First trimester screening cannot predict adverse outcomes yet
- 8 July 2014
- journal article
- review article
- Published by Wiley in Prenatal Diagnosis
- Vol. 34 (7) , 668-676
Abstract
The use of first trimester screening to detect aneuploidy has become an integral part of prenatal care. The application of similar screening algorithms to identify women at the highest risk for other adverse pregnancy outcomes in the first trimester could potentially have a major clinical impact. There has been much investigation into the ability to identify patients early in pregnancy at high risk for adverse pregnancy outcomes who may benefit from further surveillance and/or intervention. For this to be the case, however, as is true of any useful screening test, effective interventions need to be available. Unfortunately, for fetal growth restriction and stillbirth, no such interventions exist short of delivery. For preeclampsia, low dose aspirin has been demonstrated to be of benefit in specific subgroups. For preterm birth, although there are efficacious treatments, first trimester serum markers or cervical length measurements do not add significantly beyond historical or demographic factors, in prediction of preterm birth. Given the current evidence, first trimester screening, via serum or ultrasound markers, does not have sufficiently high enough positive predictive values for the development of preeclampsia, fetal growth restriction, preterm birth or stillbirth. In order to develop effective screening algorithms for adverse pregnancy outcomes in the first trimester, understanding the heterogeneous phenotype of these complications and the underlying pathophysiology is needed. © 2014 John Wiley & Sons, Ltd.Keywords
This publication has 66 references indexed in Scilit:
- First-Trimester Screening for Spontaneous Preterm Delivery with Maternal Characteristics and Cervical LengthFetal Diagnosis and Therapy, 2012
- Evaluation of 7 Serum Biomarkers and Uterine Artery Doppler Ultrasound for First-Trimester Prediction of Preeclampsia: A Systematic ReviewObstetrical & Gynecological Survey, 2011
- Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and Placental Growth Factor (PlGF) in Preeclampsia among High Risk PregnanciesPLOS ONE, 2010
- A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsiaThe Journal of Maternal-Fetal & Neonatal Medicine, 2009
- Pregnancy outcome in the setting of extremely low first trimester PAPP‐A levelsAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2009
- Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysisCanadian Medical Association Journal, 2008
- First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population-based screening study (The FASTER Trial)American Journal of Obstetrics and Gynecology, 2004
- Association of extreme first-trimester free human chorionic gonadotropin-β, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomesAmerican Journal of Obstetrics and Gynecology, 2004
- The role of uterine artery Doppler in predicting adverse pregnancy outcomeBest Practice & Research Clinical Obstetrics & Gynaecology, 2004
- The Contribution of Low Birth Weight to Infant Mortality and Childhood MorbidityNew England Journal of Medicine, 1985